Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Down 9%. What could be better?
A 10% drop is a strange way to start a steady climb. Wednesday was the pump, yesterday and today are the dump.
On what basis is the stock worth more than 0.25/share? Heck, on what basis is it worth more than .04/share?
Exactly. It's going to issue PR about cannabinoids when it hasn't yet named a PI for a clinical trial in pancreatic cancer that is supposedly starting soon?
A nice move again? You must mean a move downward because those are the only moves PMCB has made in the past 2 years. Oh sure, there's an occasional blip up a half cent, quickly negated by a fall of 0.006.
And how does his pay compare to that of CEOs of publicly traded companies that sell for less than .04 per share? Is that in your charts?
The person who holds until it's worthless is also wrong. Everybody makes a bad investment decision every now and then. But hanging on because of false hope isn't wise. If you only have a couple thousand invested, like I did, and you lose it, it's not a big deal. But continuing to buy shares when no new data or a solid clinical trial date are announced is taking on risk foolishly.
It's difficult to trust the authors when he writes this: "Besides the treatment of diabetes, PMCB is finalizing the design of its upcoming Phase 2b clinical trial for the treatment of prostate cancer. "
And all this time, we thought the phase 2B trial was in pancreatic cancer.
We're going to bypass the 3's and go straight to the 2's!
The trial date hasn't been scheduled as far as I know. Sometime in December was the stated goal; nothing has been scheduled. No participating institutions named, no principal investigator yet.
You seemed to be rooting for it to go down, especially when you were thanking people for sending the stock down to .042.
We have different strategies...I dumped most of my shares at .05. It's already down to .041 and the .03s might be here soon. If any hard progress is made toward a clinical trial, then I can always buy back in at a lower price and save a lot of money.
The 10k was worse than people thought it would be. As far as not investing anyway, it hasn't stopped me from making a lot of money on other biotechs with CEOs that know what they're doing and actually deliver on clinical trial data when they say they are. As I noted previously, if you believe that this is headed toward .02 or .01 before the clinical trial is started, why wouldn't you pull out now and buy back twice as many shares at the same price?
Not really. If you think the stock is going to drop to 0.01 before a clinical trial date is announced, why wouldn't you pull out now and reinvest at .01? That money could actually work for you in the meantime.
Conversely, people fled when they saw the 10-K.
Those curves are practically superimposable. This guy knows how to run a company alright...into the ground!
Another candidate for pancreatic cancer bit the dust today.
http://www.fiercebiotech.com/biotech/momenta-halts-phii-pancreatic-cancer-trial-after-interim-futility-analysis?utm_medium=nl&utm_source=internal&mrkid=625554&mkt_tok=eyJpIjoiWVRjMk9UZ3habVZtWVRWaiIsInQiOiJGdmpQQU5pWktnTlRhUWpUQkxTNjRsNmRXWFhZZlB5cUtqT3BPU2d0UWp1TVwvY1ZnK2k2aHhyMnlxV3lCTXBNT2hPQ3ZxdVhQSExQbnROUHFaRWp3WGdiM3hCbStxUTVWVThDQUFoSzdyVVk9In0%3D
The fact that PMCB can't secure funding for a clinical trial when there's such a great unmet med in pancreatic cancer is telling.
If you're a firm believer in PMCB, then by all means buy more shares. The rest of the investment community doesn't see it that way (stock was down yet again today) but we;re all free to invest where we see fit.
How is it misleading? These other companies are recognized as having more potential than PMCB because their fortunes aren't tied to one product. PMCB is in a bind in that it has one shot, and even that might be pushing it if it can't finance the phase 2B trial in pancreatic cancer, or if the FDA requests earlier phase study. We're talking about relative value of pipelines here and PMCB comes up short, and it comes up short in promises that haven't been delivered so far. These other companies have credibility because their pipelines are progressing while PMCB's is not.
I never invest at first opportunity when enthusiasm drives the price. Over the past month, Alnylam has risen 20%, along with much of biotech. If you'll recall, biotech had a horrible 9 months after hearings on drug prices. People are seeing that it was oversold and they've been jumping back in. PMCB has not shared in that jump because investors are examining the company and aren't seeing value.
PMCB claims to have more than one disease for which it is studying CIAB. Similar to companies that are using antisense technologies for multiple diseases. But these other companies have progressed to clinical trials in a timely fashion because they had funding. They didn't keep stalling their shareholders and therefore they gained credibility...something that PMCB lacks. Look, I am not here to argue but I think the shareholders have to move beyond cheerleading and instead examine the fundamentals. I invested, saw no progress and I dumped most of my shares. If at some point PMCB announces a trial date, I may jump back in. There's plenty of time. Money invested in PMCB these past couple of years could have been used to realize gains in other clinical stage biotechs that were more prepared.
That's my point. In order to have several clinical trials going, these companies had the faith of investors who realized the potential behind these treatments.
I do have money in all of them, and each has a few late phase clinical trials in a host of diseases.
Ionis is another. Had a 30% jump this week. There are clinical stage biotechs with their act together. PMCB isn't one of them.
I have done my due diligence, and apparently other investors have as well, which is why the stock is being ignored. The fundamentals of PMCB don't support investors coming in. I came in a couple of years ago and have shed most of my holdings, knowing that there are better opportunities out there.
Kite, Alnylum, Bellicum, Novavax to name a few.
Investors who have examined PMCB critically are shunning this stock. Meanwhile, other clinical stage biotech companies have been enjoying a run-up these past 2 weeks. I know, because I own a few of them. We need to separate desire for PMCB to do well and the facts.
Investors have had time to digest the shareholder conference call and the 10-K, and they're not impressed, given today's slide.
You're getting your chance to buy more. It's down 2% so far today.
And what does this have to do with moving it from the lab to clinical trials in a timely fashion?
There are other biotechs with advanced cell technologies that don't have such delays. Think about the CAR T therapies that require withdrawing a patient's T cells, re-engineering those cells in a lab to express T-cell receptors, and then giving them back to the patient. Quite a process, yet 2 different companies have taken this technology from the lab into clinical trials in less than 2 years, and have already reported results at numerous medical meetings and published them in peer-reviewed journals.
Correction: EXPECTED to start in December 2016. Haven't we heard this story before?
You nailed it. Absolutely nothing in the call you can hang your hat on. Wagner just said that he EXPECTS to start the pancreatic cancer trial in December. He's been giving expected start dates for more than a year.
I am listening to Wagner now. No clinical studies in pancreatic cancer until the results of yet another preclinical study are available. Expect the share price to drop further. With no timetable, investors will stay away, and rightfully so.
Of course there will be zero data. A clinical trial hasn't started yet (if ever). There is no revenue because there's no product.
This article is a year old. Where is all that interest?
Being anonymous is not a good sign for a publicly traded company. Waiting for a 6-month stop? How about waiting for a clinical trial to begin first?
A banner day for Biotech. But not PMCB. The investment community is not a believer, nor should it be. At least not yet.
Under normal circumstances, you're right about improvements in technology. One exception is pancreatic cancer, for which outcomes today are hardly better than they were 20 years ago. Lots of recent failures with potential treatments in this disease. It's an area of unmet need. That being said, PMCB has not shown that it has the ability or the finances to capitalize on this unmet need. I own shares but I realize it's a risky proposition.
They need to start presenting at meetings like ASCO.
Summed up perfectly! There will be little movement until a start date for the trial is announced.